Compounds > vlx600
Page last updated: 2024-11-11

vlx600

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

VLX600: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6410104
CHEMBL ID4788406
SCHEMBL ID20518451
MeSH IDM000611525

Synonyms (24)

Synonym
AKOS000354357
STK791986
6-methyl-3-{(2e)-2-[1-(pyridin-2-yl)ethylidene]hydrazinyl}-5h-[1,2,4]triazino[5,6-b]indole
6-methyl-n-[(e)-1-pyridin-2-ylethylideneamino]-5h-[1,2,4]triazino[5,6-b]indol-3-amine
vlx-600
unii-yzo6dg19mg
327031-55-0
yzo6dg19mg ,
ethanone, 1-(2-pyridinyl)-, 2-(6-methyl-5h-1,2,4-triazino(5,6-b)indol-3-yl)hydrazone
6-methyl-3-((2e)-2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)-5h-(1,2,4)triazino(5,6-b)indole
vlx600
6-methyl-3-((2z)-2-(1-(2-pyridinyl)ethylidene)hydrazino)-5h-[1,2,4]triazino[5,6-b]indole
SCHEMBL20518451
HY-12406
CHEMBL4788406
6-methyl-3-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)-5h-[1,2,4]triazino[5,6-b]indole
EX-A3455
mfcd01305422
CS-0011257
AS-79800
CNA03155
EN300-395210
2-[1-(2-{6-methyl-5h-[1,2,4]triazino[5,6-b]indol-3-yl}hydrazin-1-ylidene)ethyl]pyridine
Z2694498001

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Methods We conducted a multicenter, phase 1, dose escalation study to determine the safety and adverse event profile and the maximum tolerated dose and recommended phase 2 dose of VLX600."( A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.
Borad, M; Gulbo, J; Mansfield, AS; Mody, K; Nygren, P; Vemireddy, L, 2019)		0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.52 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index111.21 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (68.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		2.1310acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		5.05811,2,3-triazole
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.1710methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
wzb117
WZB117: structure in first source		2.2110
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.1510
tigecycline
[no description available]		2.5820
ConditionIndicatedRelationship StrengthStudiesTrials
Epithelial Ovarian Cancer
[description not available]		02.2110
Cancer of Ovary
[description not available]		02.6620
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.2110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.6620
Gastrointestinal Stromal Neoplasm
[description not available]		02.1710
Cancer of Gastrointestinal Tract
[description not available]		02.1710
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		02.1710
Benign Neoplasms
[description not available]		03.5911
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5911
Anoxemia
[description not available]		02.110
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.110